Clinical Trial Update: PARP (Poly (ADP-ribose) Polymerase) Inhibitor With or Without Angiogenesis Inhibitor in Homologous Recombination Deficient Primary Ovarian Cancer, Fallopian-Tube Cancer, or Primary Peritoneal Cancer [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/Phase 3 clinical trial evaluates a PARP inhibitor with or without an angiogenesis inhibitor in patients with homologous recombination deficiency-assoc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• PARP inhibitor
• angiogenesis inhibitor

Snippet

Sponsor: N.N. Alexandrov National Cancer Centre | Conditions: Ovarian Cancer, Fallopian Tube Cancers | Phase 2, Phase 3 | Status: RECRUITING